Merck's $9.2 billion acquisition of Cidara Therapeutics boosts influenza prevention

Merck announced the acquisition of Cidara Therapeutics for US $221.5 per share in cash, with a total transaction value of approximately US $9.2 billion and is expected to be completed in the first quarter of 2026. The acquisition aims to obtain Cidara's long-acting influenza antibody drug and promote the development of influenza prevention.

Related stocks

Acquired US $9.2 billion from Merck (MRK.US) to acquire Cidara (CDTX.US), the stock price doubled before the market opened

智通财经·11月 14, 2025

Acquired US $9.2 billion from Merck (MRK.US) to acquire Cidara (CDTX.US), the stock price doubled before the market opened

Merck acquires Cidara Therapeutics for $221.5 per share in cash

智通财经网·11月 14, 2025

Merck acquires Cidara Therapeutics for $221.5 per share in cash

Cidara Therapeutics shares continue to rise, jumping 104% premarket as Merck agreed to buy the company for about $9.2 billion

美股速递·11月 14, 2025

Cidara Therapeutics shares continue to rise, jumping 104% premarket as Merck agreed to buy the company for about $9.2 billion

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

MT Newswires Live·11月 14, 2025

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

Merck's proposed acquisition of Cidara Therapeutics, Inc., diversifying its portfolio with late-stage antivirals

美股速递·11月 14, 2025

Merck's proposed acquisition of Cidara Therapeutics, Inc., diversifying its portfolio with late-stage antivirals

Merck: Under the merger and acquisition agreement, Merck, through its subsidiaries, will acquire all outstanding shares of Cidara

美股速递·11月 14, 2025

Merck: Under the merger and acquisition agreement, Merck, through its subsidiaries, will acquire all outstanding shares of Cidara

Merck Pharmaceuticals will acquire Cidara Therapeutics for $221.50 per share in cash.

智通财经·11月 14, 2025

Merck Pharmaceuticals will acquire Cidara Therapeutics for $221.50 per share in cash.

Cidara Therapeutics' pre-market gains in U.S. stocks expanded to 105%. Merck will acquire the company for $221.5 per share in cash. The transaction is expected to take place in 20

智通财经·11月 14, 2025

Cidara Therapeutics' pre-market gains in U.S. stocks expanded to 105%. Merck will acquire the company for $221.5 per share in cash. The transaction is expected to take place in 20

Tiger Brokers

Merck's $9.2 billion acquisition of Cidara Therapeutics boosts influenza prevention

Acquired US $9.2 billion from Merck (MRK.US) to acquire Cidara (CDTX.US), the stock price doubled before the market opened

Merck acquires Cidara Therapeutics for $221.5 per share in cash

Cidara Therapeutics shares continue to rise, jumping 104% premarket as Merck agreed to buy the company for about $9.2 billion

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

Merck's proposed acquisition of Cidara Therapeutics, Inc., diversifying its portfolio with late-stage antivirals

Merck: Under the merger and acquisition agreement, Merck, through its subsidiaries, will acquire all outstanding shares of Cidara

Merck Pharmaceuticals will acquire Cidara Therapeutics for $221.50 per share in cash.

Cidara Therapeutics' pre-market gains in U.S. stocks expanded to 105%. Merck will acquire the company for $221.5 per share in cash. The transaction is expected to take place in 20

Most Discussed